Subject: Synergen's Shares Continue to Surge 
Date: Published: 8/28/91 (49 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    OTC Focus:
    Nasdaq Stocks Inch Up to New High;
    Synergen's Shares Continue to Surge
    ----
    By Anne Newman and Michael A. Pollock
    Staff Reporters of The Wall Street Journal

    NEW YORK -- Over-the-counter stocks edged up to another
 new high as companies with exciting new technologies and
 products caught investors' fancy.
    Synergen, which has surged 37% in the past week, climbed
 another 2 1/2 to 57 as investors continue to be excited about
 the Boulder, Colo., company's prospects for treating such
 ailments as rheumatoid arthritis, toxic and septic shock,
 cancer, bed sores and skin ulcers with its pipeline of
 genetically engineered products.  Synergen's shares have
 skyrocketed from 8 1/2 about a year ago.
    For the short term, Synergen has become too expensive,
 says John Kaweske, manager of biotechnology stocks for the
 Financial Strategic Portfolio funds in Denver.  Mr. Kaweske,
 who has cashed in his gains on about 25% of his four-year-old
 Synergen holdings, says he doesn't expect the company to win
 final approval to market a product before 1994.  But he adds
 that he's hanging on to the rest because of what he calls the
 company's blockbuster potential.
    Investors are closely watching two products now being
 tested by Synergen:  a human protein known as Fibroblast
 Growth Factor, which is being developed to treat chronic skin
 ulcers and bed sores; and Interleukin-1 receptor antagonist,
 or IL-1ra, which Synergen is testing for the treatment of
 inflammatory bowel disease, rheumatoid arthritis, septic
 shock and certain types of cancer.

[68 lines irrelevant to AIDS were omitted.  -- sysop]

    Meanwhile, after jumping nearly 15% Monday, shares of
 Immune Response rose another 1 1/4 to 22 5/8.  The Carlsbad,
 Calif., company's shares are said to be benefitting from
 favorable expectations involving tests of Immune Response's
 therapeutic vaccine for HIV, the virus that causes AIDS.  

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]